ESC 2020: Novartis’ inclisiran continues to impress with post-hoc analysis
PCSK9 inhibitors have largely been limited to patients who are unable to lower LDL-C levels with conventional lipid-lowering therapies. Credit: Shidlovski / Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more